Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Cassidy KC"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Nguyen E; Biological Sciences, University of Pittsburgh, Pittsburgh, PA, United States of America., Sosa JA; Biological Sciences, University of Pittsburgh, Pittsburgh, PA, United States of America., Cassidy KC; BIOVIA, Dassault Systèmes, Waltham, MA, United States of America., Berman AJ; Biological Sciences, University of Pittsburgh, Pittsburgh, PA, United States of America.
Publikováno v:
PloS one [PLoS One] 2024 Aug 27; Vol. 19 (8), pp. e0308574. Date of Electronic Publication: 2024 Aug 27 (Print Publication: 2024).
Autor:
Martin JA; Eli Lilly and Company, Indianapolis, USA. Electronic address: martin_jennifer_a@lilly.com., Czeskis B; Eli Lilly and Company, Indianapolis, USA., Urva S; Eli Lilly and Company, Indianapolis, USA., Cassidy KC; Eli Lilly and Company, Indianapolis, USA.
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2024 Nov 01; Vol. 202, pp. 106895. Date of Electronic Publication: 2024 Sep 05.
Autor:
Young GC; GSK Research &Development Ltd., Stevenage, UK., Spracklin DK; Pfizer Inc., Groton, Connecticut, USA., James AD; Novartis, Basel, Switzerland., Hvenegaard MG; H. Lundbeck A/S, Copenhagen, Denmark., Pedersen ML; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Wagner DS; AbbVie, North Chicago, Illinois, USA., Georgi K; The Healthcare Business of Merck KGaA, Darmstadt, Germany., Schieferstein H; The Healthcare Business of Merck KGaA, Darmstadt, Germany., Bjornsdottir I; Novo Nordisk, Maaloev, Denmark., Romeo AA; Roche Pharma Research and Early Development, Basel, Switzerland., Cassidy KC; Eli Lilly and Company, Indianapolis, Indiana, USA., Da-Violante G; Technologie Servier, Orleans, France., Blech S; Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Schulz SI; Bayer AG, Wuppertal, Germany., Cuyckens F; Janssen R&D, Beerse, Belgium., Nguyen MA; Sanofi, R&D, Frankfurt, Germany., Scarfe G; Sosei Heptares, Great Abington, Cambridge, UK.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 May; Vol. 115 (5), pp. 931-938. Date of Electronic Publication: 2023 Dec 22.
Autor:
Cuyckens F; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.) fcuycken@its.jnj.com., Hvenegaard MG; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Cassidy KC; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Spracklin DK; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., James AD; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Pedersen ML; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Scarfe G; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Wagner DS; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Georgi K; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Schulz SI; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Schieferstein H; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Bjornsdottir I; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Romeo AA; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Da Violante G; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Blech S; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Moliner P; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)., Young GC; Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Feb 14; Vol. 52 (3), pp. 153-158. Date of Electronic Publication: 2024 Feb 14.